Business Wire

IntegenX Applauds the Passage of the Rapid DNA Act of 2017

Del

IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations.

Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement.

IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman James Sensenbrenner (R-WI) and lead co-sponsor Congressman Eric Swalwell (D-CA), along with the other 12 Senate and 24 House co-sponsors for their support.

“Today marks a landmark day in more efficiently fighting crime and supporting law enforcement,” stated Robert Schueren, President and CEO of IntegenX. “IntegenX products have already enabled numerous DNA profile uploads to our nation’s DNA database (CODIS). We look forward to the updated FBI guidelines, and subsequent CODIS uploads from the booking environment.”

“Rapid DNA is a promising new technology and an effective tool for law enforcement – I’m thrilled to be seeing it signed into law. This technology will help quickly identify arrestees and offenders, reduce the overwhelming backlog in forensic DNA analysis, and make crime fighting more efficient while helping to prevent future crimes from occurring. It will also save time and taxpayer dollars,” commented Congressman Sensenbrenner, Chairman of the House Judiciary Subcommittee on Crime, Terrorism, Homeland Security and Oversight.

“This bill will help law enforcement agencies solve crimes faster and help those wrongfully accused to be exonerated from crimes they did not commit—almost instantly. The Rapid DNA Act updates the statutory framework in how DNA samples are entered into the FBI’s Combined DNA Index System by allowing the use of this remarkable Rapid DNA technology,” stated Senator Hatch.

“I’m glad we were able to reach bipartisan consensus to enact this law. This new law will help law enforcement agencies across the nation use a faster and more powerful tool to protect and serve our communities, and to attain justice for victims,” said Congressman Swalwell (D-CA).

“I applaud the passage of the Rapid DNA Act by the U.S. Congress. This update to current DNA law, enabling use of Rapid DNA analysis by our local law enforcement officials, is a tremendous victory for our communities, bringing swift justice to survivors of sexual assault and helping to prevent assaults by repeat offenders,” said Debbie Smith, founder of H-E-A-R-T, Inc. (Hope Exists After Rape Trauma). “I believe that this Act will help free up crime laboratory resources, allowing them to be more focused on the testing of backlogged rape kits, a problem that together with Congress, we have been working on for the past 15 years.”

“We’re very excited to see the passage of the Rapid DNA Act of 2017,” said Mai Fernandez, Executive Director of National Center for Victims of Crime. “Having results for DNA tests while suspects are still in custody should further contribute to the safety of our communities, and ultimately potentially reduce rape kit backlog.”

To further facilitate the adoption and validation of Rapid DNA technology by state forensic laboratories conducting arrestee testing, IntegenX is announcing the “Act in 2017” program, providing state forensic laboratories with cost-effective introductory pricing of the RapidHIT ID System and RapidLINK software. The RapidHIT ID system’s pivotal development validation study was recently published in the prestigious Forensic Science International: Genetics http://www.fsigenetics.com/article/S1872-4973(17)30005-4/pdf

About IntegenX

IntegenX Inc. is the market leader of Rapid Human DNA identification technology. IntegenX technology platforms integrate advanced fluidics, optics, and biochemistry capabilities, along with cutting edge software, to produce sample-to-answer products for DNA-based human identity testing for forensics and law enforcement applications. For more information, please visit www.integenx.com. IntegenX, the IntegenX logo, RapidHIT, and RapidLINK are the registered trademarks of IntegenX Inc.

Contact information

IntegenX Inc.
David V. Smith, 925-701-3400
Chief Operating Officer
davids@integenx.com
Fax: 925-574-7373

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

LivaNova Enters into Binding Letter of Intent to Sell its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation for $190 Million20.11.2017 08:43Pressemelding

LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) and MicroPort Scientific Corporation (HK:00853) (“MicroPort”) today announced that the companies have entered into a binding Letter of Intent (“LOI”) for the sale of LivaNova’s Cardiac Rhythm Management (“CRM”) Business Franchise to MicroPort for $190 million in cash. The CRM Business Franchise develops, manufactures and markets products for the diagnosis, treatment and management of heart rhythm disorders and heart failures. CRM products include high-voltage defibrillators, cardiac resynchronization therapy devices and low-voltage pacemakers. The CRM Business Franchise generated approximately $249 million in net sales in fiscal year 2016 and has approximately 900 employees with operations chiefly in Clamart, France; Saluggia, Italy; and Santo Domingo, Dominican Republic. MicroPort is a leading medical device company, focused on innova

Chugai's Bispecific Antibody Emicizumab Meets Primary Endpoint in Phase lll Study20.11.2017 08:29Pressemelding

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the primary endpoint has been met for the global phase lll HAVEN 3 (NCT02847637) study evaluating emicizumab (ACE910) subcutaneous injection, once a week and once every two weeks, in patients with hemophilia A (12 years of age or older) without inhibitors to factor Vlll. A statistically significant reduction in the number of bleeds was confirmed in patients treated with emicizumab prophylaxis compared to those receiving no prophylactic treatment. The study also met a secondary endpoint that once-weekly emicizumab prophylaxis was superior to factor VIII prophylaxis, as demonstrated by a statistically significant and clinically meaningful reduction in treated bleeds in an intra-patient comparison of patients receiving emicizumab prophylaxis compared to their prior factor VIII prophylaxis. The most common adverse events with em

Fiorano Launches PSD2 Solution for Banks for Seamless Regulatory Compliance20.11.2017 08:00Pressemelding

Fiorano Software, a proven global leader in Integration Middleware and API Management, today announced the launch of Fiorano PSD2, a platform solution enabling banks to comply with the European Union’s Revised Payment Service Directive (PSD2) regulations. Fiorano’s end-to-end PSD2 solution is built on the industry's leading banking Integration and API Management infrastructure serving as an onramp for future eDigital Banking initiatives. Banks across Europe need to be PSD2 compliant by January 2018. They are also facing severe competition from FinTechs to improve online payments, customer engagement experiences and making cross-border payments safer. “By building on PSD2 as a solution on top of a tightly integrated API Management and ESB platform, Fiorano masks complex technical details, dramatically simplifies the time and effort for compliance,” said Mr. Atul Saini, CEO of Fio

Synteract Thought Leaders to Speak & Exhibit at Partnerships in Clinical Trials Europe in Amsterdam20.11.2017 08:00Pressemelding

(Booth #17) – Thought leaders from Synteract, a full-service, international contract research organization (CRO), will exhibit and present at Partnerships in Clinical Trials Europe (PCT), November 28-29, Amsterdam, Netherlands. With awareness of the shifting CRO landscape and the complexity this represents to biopharma companies as they make critical outsourcing decisions, Synteract invites attendees to “Pause to rethink what matters most from your CRO.” Vice President, Global Medical and Regulatory Affairs at Synteract, Dr. Martine Dehlinger-Kremer, will speak on “The EU Clinical Trials Regulation: Are you prepared for its implementation?” at the event on Tuesday, November 28 at noon. She will address how evolving industry needs are driving momentum towards implementation of a new regulation governing clinical trials, the expected impact on sponsors and necessary steps toward p

Record Attendance at Japan Content Showcase 2017!20.11.2017 03:00Pressemelding

Japan Content Showcase 2017 was held October 23-26 at Ikebukuro Sunshine City and the Shibuya Excel Hotel Tokyu. A record 19,549 people participated in sales meetings, excluding the TIMM Showcase Live. Other new records this year were 371 exhibiting groups from 27 countries and regions and 1,549 buyers from 48 countries and regions. There was a significant increase in overseas buyers this year, the 1022 foreign registrations representing an increase of more than 10% over last year. The number of non-Japanese Asian buyers increased by 6%, North Americans by 13%, South Americans by 44%, and Europeans by 49%. The number of Middle Eastern buyers doubled, and there were more than five times the number of Russian buyers as last year. French buyers were up 70%, Italians 60%, British 75%, and Germans 50%. Business matching was a new service offered by the organizers this year. Meeti

Shell, bio-bean and Coffee-Drinkers Collaborate to Help Power London’s Buses20.11.2017 00:01Pressemelding

Shell and bio-bean announce that together they are helping to power some of London’s buses using a biofuel made partly from waste coffee grounds. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005060/en/ Shell and bio-bean announce that together they are helping to power some of London's buses using a biofuel made partly from waste coffee grounds (Photo: Business Wire) The B20 biofuel contains a 20% bio-component which contains part coffee oil. The biofuel is being added to the London bus fuel supply chain and will help to power some of the buses; without need for modification. Biofuel provides a cleaner, more sustainable energy solution for buses across London’s network by decreasing emissions1. “Our Coffee Logs have already become the fuel of choice for households looking for a

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom